Abstract
Objective
There is an association between latitude, relative vitamin D deficiency and risk of multiple sclerosis (MS), and an association between vitamin D and disease progression. We have performed a meta-analysis with the aim of investigating the role of therapeutic vitamin D in MS.
Methods
A systematic search of databases was performed to identify clinical trials assessing vitamin D in patients with relapsing–remitting MS. Studies were selected based on inclusion and exclusion criteria. Analysis was performed using RevMan 5.3 software.
Results
Twelve studies involving 950 patients were included in the final analysis. Studies were divided into four groups because of heterogeneity in study design. Studies were judged to be at low or unclear risk of bias, except in three studies, and this was confirmed by funnel plots. No statistically significant difference was seen for any of the outcome measures. There were non-significant trends in favour of vitamin D for all outcome measures, particularly when only placebo-controlled studies were included. Dose comparison studies showed a significant increase in annualised relapse rate (mean difference 0.15 [95%CI 0.01–0.30]) and non-significant trends of increased Expanded Disability Status Scale and gadolinium-enhancing lesions for the higher-dose arms.
Conclusion
These findings suggest that vitamin D supplementation may have a therapeutic role in the treatment of MS. However, there is uncertainty with regard to the most appropriate dose, with high doses potentially being associated with worse outcomes. There remains the need for further well-performed randomised, dose-ranging, placebo-controlled trials of vitamin D in MS.
Similar content being viewed by others
Abbreviations
- ARR:
-
Annualised relapse rate
- CI:
-
Confidence interval
- EDSS:
-
Expanded Disability Status Scale
- MRI:
-
Magnetic resonance imaging
- MS:
-
Multiple sclerosis
References
Compston A, Coles A, Multiple sclerosis (2008) Lancet 372:1502–1517. https://doi.org/10.1016/S0140-6736(08)61620-7
O’Gorman C, Lucas R, Taylor B (2012) Environmental risk factors for multiple sclerosis: a review with a focus on molecular mechanisms. Int J Mol Sci 13:11718–11752. https://doi.org/10.3390/ijms130911718
ANZgene Multiple Sclerosis Genetics Consortium (2009) Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat Genet 41:824–828. https://doi.org/10.1038/ng.396
Simpson S Jr, Blizzard L, Otahal P et al (2011) Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. J Neurol Neurosurg Psychiatry 82:1132–1141. https://doi.org/10.1136/jnnp.2011.240432
Munger KL, Zhang SM, O’Reilly E et al (2004) Vitamin D intake and incidence of multiple sclerosis. Neurology 62:60–65
Simpson S Jr, Taylor B, Blizzard L et al (2010) Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol 68:193–203. https://doi.org/10.1002/ana.22043
Goodkin DE, Hertsgaard D (1989) Seasonal variation of multiple sclerosis exacerbations in North Dakota. Arch Neurol 46:1015–1018
Smolders J, Menheere P, Kessels A et al (2008) Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler 14:1220–1224. https://doi.org/10.1177/1352458508094399
Mowry EM, Waubant E, McCulloch CE et al (2012) Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann Neurol 72:234–240. https://doi.org/10.1002/ana.23591
van der Mei IA, Ponsonby AL, Dwyer T et al (2007) Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J Neurol 254:581–590. https://doi.org/10.1007/s00415-006-0315-8
Wingerchuk DM, Lesaux J, Rice GP et al (2005) A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 76:1294–1296. https://doi.org/10.1136/jnnp.2004.056499
Norman AW (2008) From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health. Am J Clin Nutr 88:491S–499S
Hewer S, Lucas R, van der Mei I et al (2013) Vitamin D and multiple sclerosis. J Clin Neurosci 20:634–641. https://doi.org/10.1016/j.jocn.2012.10.005
Hewison M, Burke F, Evans KN et al (2007) Extra-renal 25-hydroxyvitamin D3-1alpha-hydroxylase in human health and disease. J Steroid Biochem Mol Biol 103:316–321. https://doi.org/10.1016/j.jsbmb.2006.12.078
Toell A, Polly P, Carlberg C (2000) All natural DR3-type vitamin D response elements show a similar functionality in vitro. Biochem J 352 Pt 2:301–309
May E, Asadullah K, Zugel U (2004) Immunoregulation through 1,25-dihydroxyvitamin D3 and its analogs. Curr Drug Targets Inflamm Allergy 3:377–393
McDonald WI, Compston A, Edan G et al (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121–127
Morrissey SP, Miller DH, Kendall BE et al (1993) The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study. Brain 116(Pt 1):135–146
Wan X, Wang W, Liu J et al (2014) Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 14:135. https://doi.org/10.1186/1471-2288-14-135
Petitti DB (2000) Meta-analysis, decision analysis, and cost -effectiveness analysis: methods for quantitative synthesis in medicine, 2nd edn. Oxford University Press, Oxford, p 306
Higgins JP, Thompson SG, Deeks JJ et al (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560. https://doi.org/10.1136/bmj.327.7414.557
Merck K (2017) A multicentre study of the efficacy and safety of supplementary treatment with cholecalciferol in patients with relapsing multiple sclerosis treated with subcutaneous interferon beta-1a 44 ug 3 times weekly (CHOLINE), https://clinicaltrials.gov/ct2/show/NCT01198132. Accessed 14 Feb 2018
Merck K (2017) Supplementation of VigantOL® oil versus placebo as add-on in patients with relapsing remitting multiple sclerosis receiving Rebif® treatment (SOLAR), https://clinicaltrials.gov/ct2/show/NCT01285401. Accessed 14 Feb 2018
O’Connell K, Sulaimani J, Basdeo SA et al (2017) Effects of vitamin D3 in clinically isolated syndrome and healthy control participants: a double-blind randomised controlled trial. Mult Scler J Exp Transl Clin 3:2055217317727296. https://doi.org/10.1177/2055217317727296
Salari M, Janghorbani M, Etemadifar M et al (2015) Effects of vitamin D on retinal nerve fiber layer in vitamin D deficient patients with optic neuritis: preliminary findings of a randomized, placebo-controlled trial. J Res Med Sci 20:372–378
Stein MS, Liu Y, Gray OM et al (2011) A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology 77:1611–1618. https://doi.org/10.1212/WNL.0b013e3182343274
Golan D, Halhal B, Glass-Marmor L et al (2013) Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties. BMC Neurol 13:60. https://doi.org/10.1186/1471-2377-13-60
Sotirchos ES, Bhargava P, Eckstein C et al (2016) Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. Neurology 86:382–390. https://doi.org/10.1212/WNL.0000000000002316
Kampman MT, Steffensen LH, Mellgren SI et al (2012) Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Mult Scler 18:1144–1151. https://doi.org/10.1177/1352458511434607
Soilu-Hanninen M, Aivo J, Lindstrom BM et al (2012) A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 83:565–571. https://doi.org/10.1136/jnnp-2011-301876
Shaygannejad V, Janghorbani M, Ashtari F et al. Effects of adjunct low-dose vitamin d on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebo-controlled trial. Mult Scler Int 2012; 2012: 452541. https://doi.org/10.1155/2012/452541
Achiron A, Givon U, Magalashvili D et al (2015) Effect of Alfacalcidol on multiple sclerosis-related fatigue: A randomized, double-blind placebo-controlled study. Mult Scler 21:767–775. https://doi.org/10.1177/1352458514554053
Derakhshandi H, Etemadifar M, Feizi A et al (2013) Preventive effect of vitamin D3 supplementation on conversion of optic neuritis to clinically definite multiple sclerosis: a double blind, randomized, placebo-controlled pilot clinical trial. Acta Neurol Belg 113:257–263. https://doi.org/10.1007/s13760-012-0166-2
Overton RC (1998) A comparison of fixed-effects and mixed (random-effects) models for meta-analysis tests of moderator variable effects. Psych Meth 3:354–379
The IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655–661
Acknowledgements
We are grateful to Dr Karen O’Connell and Prof Michael Hutchinson for providing mean (SD) data for change in EDSS in their study. We are grateful to Prof Ariel Miller and Dr Daniel Golan for providing mean (SD) data for change in EDSS from their study. We are also grateful to Prof Peter Calabresi, Prof Samia Khoury, Dr Jan-Markus Dörr, and Prof Masoud Etemadifar and Prof William Camu for clarifying the status of their studies. We are extremely grateful to Dr Mark Stein for reviewing and providing invaluable comments on drafts of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
HB, BVT and SAB are currently principal investigators on a phase II clinical trial of vitamin D in MS sponsored by Multiple Sclerosis Research Australia. Otherwise, the authors have no conflicts of interest.
Ethical standard
None.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
McLaughlin, L., Clarke, L., Khalilidehkordi, E. et al. Vitamin D for the treatment of multiple sclerosis: a meta-analysis. J Neurol 265, 2893–2905 (2018). https://doi.org/10.1007/s00415-018-9074-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-018-9074-6